Abstract
In recent months, cases of IBD have been reported in the context of treatment with secukinumab, a monoclonal antibody that blocks IL-17A and which is used in the treatment of certain rheumatic disorders. We present a case of a patient with psoriatic arthritis, with a first-degree relative who had suffered ulcerative colitis, who presented with onset ulcerative colitis in the weeks following treatment initiation with this drug.
Publication types
-
Case Reports
-
Letter
-
Review
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Arthritis, Psoriatic / drug therapy
-
Colitis, Ulcerative / chemically induced*
-
Diarrhea / chemically induced
-
Gastrointestinal Hemorrhage / chemically induced
-
Humans
-
Interleukin-17 / antagonists & inhibitors*
-
Male
-
Rectum
Substances
-
Antibodies, Monoclonal, Humanized
-
IL17A protein, human
-
Interleukin-17
-
secukinumab